A new market analysis projects the global myelodysplastic syndrome (MDS) treatment market will grow from an estimated value ...

Infection is the leading cause of death in LR-MDS patients, responsible for 24.6% of deaths within a year of diagnosis. Key risk factors for infection include intermediate or higher IPSS-R risk ...

New long-term data from the COMMANDS trial reveals that luspatercept significantly prolongs survival for patients with low-risk MDS.

Lenalidomide for TD MDS-5q and ESAs has been used successfully for decades, and although HMAs are active in LR-MDS, their use should be considered carefully. 41, 71 - 74 Since 2017, ESAs such as ...

Reblozyl (luspatercept) has become the new standard of care for patients with low-risk myelodysplastic syndromes (MDS) facing anemia (low red blood cell count), an expert explained in an interview ...